Download BIOGRAPHICAL SKETCH Katherine T. Morris Assistant Professor

Principal Investigator/Program Director (Last, First, Middle):
Morris, Katherine T.
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Katherine T. Morris
Assistant Professor, Division of Surgical Oncology,
Department of Surgery, University of New Mexico.
eRA COMMONS USER NAME
KTMorris
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
DEGREE
(if applicable)
YEAR(s)
BS
MD
1988-1992
1992-1996
University of Washington, Seattle, Washington
Oregon Health and Science University, Portland, Oregon
FIELD OF STUDY
Mathematics
Medicine
A. Personal Statement
As a Surgical Oncologist with a clinical focus on gastrointestinal tumors, I will use my expertise in the natural
history and clinical management of gastric and colorectal cancers to facilitate this project examining pathways
of chronic inflammation and their relation to the development of these malignancies. While there is a clear
clinical link between conditions causing chronic inflammation and certain cancers (H. pylori infection and
gastric adenocarcinoma, inflammatory bowel disease and colorectal cancer), the molecular mechanisms by
which this occurs have not been fully elucidated. As an Assistant Professor recently recruited to UNM, I have
actively sought collaborations with promising scientists such as Dr. Beswick in an effort to further this type of
clinically relevant research which is critically necessary to rapidly translate laboratory based scientific
observations into new treatment options for patients.
I am particularly interested in this project as findings regarding the mechanisms by which chronic inflammation
can influence gastrointestinal tumors such as gastric and colorectal cancer may also have applicability to the
development of other inflammation related GI cancers such as gallbladder cancer and cholangiocarcinoma,
potentially leading to new screening and treatment options for all these tumors which, combined, represent a
significant public health concern.
B. Positions and Honors
Positions and Employment
2003 - 1996
Resident in General Surgery, Oregon Health and Science University, Portland, OR
2005 –2003
Surgical Oncology Fellow, Memorial Sloan Kettering Cancer Center, New York, NY
2006 –2005
Surgical Oncologist, Oregon Surgical Consultants, Portland, OR
2010 –2005
Medical Director of Cancer Research, Legacy Health System, Portland, OR
2010 –2007
NW Surgical Oncology, PC, Surgical Oncologist, Portland, OR
2010 –2007
Medical Director of Hepatobiliary Program, Legacy Health System, Portland, OR
2010Assistant Professor, Division of Surgical Oncology, Department of Surgery, University of
New Mexico, Albuquerque, NM
Other Experience and Professional Memberships
2007 Member, American Association for Cancer Research
2006 Member, Society of Surgical Oncology
2005 Member, American Society of Clinical Oncology
2005 Member, American College of Surgeons
2010 – 2006
Member, Human Services Commission, State of Oregon, Genetics Advisory
Subcommittee
2009-2010
State Chair, American College of Surgeons Commission on Cancer, Oregon.
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page
1
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, First, Middle):
Morris, Katherine T.
Honors
2000
2000
1999, 2000, & 2001
2001
2001
2009
2009
Oregon Health Sciences University Alumni Association Resident Paper Award
American Radium Society Young Oncologist Travel Grant
Baker-Moseley Award in Surgical Oncology - American College of Surgeons
American Association for Endocrine Surgeons Best Basic Science Paper Award
Pacific Coast Surgical Society Resident Paper Award
Portland Business Journal Forty Under Forty
Portland Monthly Magazine Top Doctors, Surgical Oncology
C. Selected Peer-reviewed Publications (in chronological order):
1. Thompson, S. J., Ordonez A. N., Ashley, M. D., Jessick, V. J., Murphy, B., Gafken, P., Henshall, D.,
Morris, K., Simon, R. P., & Meller, R. “Identification of a novel Bim E3 ligase, tri-partite motif containing
protein 2, and its role in rapid ischemic tolerance induced neuroprotection.” In Press Journal of
Biological Chemistry 2011
2. Morris KT, Gönen M, Schwartz L, Tuorto S, DeMatteo R, D’Angelica M, Jarnagin WR, Fong Y. “A
Simple
Measurement of Intra-abdominal Fat Predicts Outcome After Upper Abdominal Surgery.”
Archives of Surgery, November 2010; 145(11): 1069-1073.
3. Sambasivan C, Deveney K, Morris KT. “Oncologic Outcomes after Resection of Rectal Cancer:
Laparoscopic versus Open Approach.” American Journal of Surgery, May 2010; 199: 599-603.
4. McLaughlin SA, Wright MJ, Morris KT, Sampson MR, Brockway JP, Hurley KE, Riedel ER, and Van
Zee KJ. “Prevalence of lymphedema in 936 women with breast cancer 5 years after sentinel lymph
node biopsy or axillary dissection: I. Objective measurements.” Journal of Clinical Oncology, November
2008; 26(32): 5213-9.
5. McLaughlin SA, Wright MJ, Morris KT, Sampson MR, Brockway JP, Hurley KE, Riedel ER, and Van
Zee KJ. “Prevalence of lymphedema in 936 women with breast cancer 5 years after sentinel lymph
node biopsy or axillary dissection: II. Patient perceptions and precautionary behaviors.” Journal of
Clinical Oncology, November 2008; 26(32): 5220-6.
6. Morris KT, Busam KJ, Bero S, Patel A, Brady MS. “Primary cutaneous melanoma with regression
does not require a lower threshold for sentinel lymph node biopsy.” Annals of Surgical Oncology,
January 2008; 15(1): 316-322.
7. Morris KT, Song TJ, and Fong Y. “Recent advancements in diagnosis and treatment of metastatic
colorectal cancer to the liver.” Surgical Oncology, November 2006; 15(3): 129-134.
8. Morris AM, Flowers CR, Morris KT, Schmidt WA, Pommier RF, and Vetto JT. “Comparing the costeffectiveness of the triple test score to traditional methods for evaluating palpable breast masses.”
Medical Care, August 2003; 41(8): 962-971.
9. Morris KT, Toth-Fejel S, Schmidt J, Fletcher WS, and Pommier RF. “High DHEA predicts breast
cancer cell growth in tissue culture: A renewed role for adrenalectomy.” Surgery, December 2001;
130(6): 947-53.
10. Morris KT, Pommier RF, Morris A, Schmidt WA, Beagle G, Alexander PW, Toth-Fejel S, Schmidt J,
Vetto JT. “Usefulness of the triple test score for palpable breast masses.” Archives of Surgery,
September, 2001; 136(9): 1008-1013.
11. Morris KT, Stevens J, Fletcher WS, Pommier RF, and Vetto JT. “Usefulness of preoperative
lymphoscintigraphy for the identification of SLN location in melanoma.” American Journal of Surgery,
May 2001; 181: 423-426.
12. Morris KT, Johnson N, Dorsey P, Krasikov N, and Allen M. “Genetic counseling impacts decision for
prophylactic surgery for patients perceived to be at high risk for breast cancer.” American Journal of
Surgery, May 2001; 181: 431-433.
13. Morris KT, Marquez C, and Vetto JT. “Prevention of local recurrence after surgical debulking of nodal
and subcutaneous melanoma deposits by hypofractionated radiation therapy.” Annals of Surgical
Oncology, October 2000; 7(9): 680-4.
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page
2
Continuation Format Page
Principal Investigator/Program Director (Last, First, Middle):
Morris, Katherine T.
14. Morris KT, Johnson N, Homer L, and Walts D. “A comparison of complementary therapy use between
breast cancer patients and patients with other primary tumor sites.” American Journal of Surgery, May
2000; 179(5): 407-11.
15. Morris KT, Pommier RF, Vetto JT. “Office based wire guided open breast biopsy under local
anesthesia is accurate and cost effective.” American Journal of Surgery, May 2000; 179(5): 422-5.
D. Research Support
Completed Research Support
LGSF
Morris (PI)
Legacy Good Samaritan Foundation Grant
10/01/2005-10/01/2010
Legacy Health System Tumor Bank.
The goal of this project was to establish a prospectively maintained collection of tumor tissue with ongoing
patient status updates. Confidentiality is assured by a code number linkage which is stored in our secure
Cancer Registry. The tissue is used for translational research and all participating patients give informed
consent. This project is ongoing under another PI since my departure.
Role: PI
LGSF
Morris (PI)
Legacy Good Samaritan Foundation Grant
04/01/2008-03/01/2009
Combined selective internal radiation therapy and radiofrequency ablation for primary and secondary hepatic
malignancies with correlative study of treated samples.
The goals of this project were: to assess the safety of combined selective internal radiation therapy and
radiofrequency ablation for primary and secondary hepatic malignancies, and to perform analysis of markers of
angiogenesis and apoptosis in the treated tissues.
Role: Co-PI
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page
2
Continuation Format Page